Komori
Kidswell Bio (4584) · InitiativeFirst stated

Domestic and overseas supply of dental pulp stem cells through 住商ファーマインターナショナル

First written in FY2020-Q2. . Latest entry: FY2020-Q2.

1entries
1years
0from disclosures
Share on X
How it moved
Same theme, other companies
Building a sales and supply channel for dental pulp stem cellsA theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2020-Q2First statedAnnual report

    「In October of the same year, the Company formed a partnership with Sumisho Pharma International Co., Ltd., which specialises in the distribution and sale of biological resources, and began supplying dental pulp stem cells stably and promptly to researchers in Japan and overseas through the company's logistics and distribution channels. This will accelerate research and development of new medical treatments using dental pulp stem cells.」

    The Company began efforts to supply dental pulp stem cells stably and promptly to researchers in Japan and overseas through Sumisho Pharma International's logistics and distribution channels.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Kidswell Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Domestic and overseas supply of dental pulp stem cells through 住商ファーマインターナショナル | Kidswell Bio Corporation (4584) | Komori